Evaluation of the relationship between various histopathological types of primary malignant thyroid carcinoma and blood groups


  • Yadgar Aziz Abdullah Medical Laboratory Department, College of Health and Medical Technology, Sulaimani Polytechnic University, Sulaimani city, Kurdistan, Iraq
  • Ali Hattem Hussein Nursing Department, College of Health and Medical Technology, Sulaimani Polytechnic University, Sulaimani city, Kurdistan, Iraq


Background: The ABO and Rh system have a great association
to different kind of malignancy as mentioned in the literature.
The data about prevalence of blood group with thyroid
malignancies were limited in the literature; we aimed to record
the relationship of different ABO and Rh blood groups with
different malignant thyroid tumors.
Methodology: the demographics, ABO blood group, Rh factor,
histopathological type of malignant thyroid tumors were
recorded for each patient with malignant thyroid tumor (MTT);
then we evaluated the association between different blood group
types with different histopathological pattern.
Results: the commonest type of malignant thyroid carcinoma
was Papillary thyroid carcinoma (PTC) [n=46, (92%)], while all
other types were uncommon, they were follicular thyroid
carcinoma [(n=1) 2%], medullary thyroid carcinoma [(n=1) 2%],
Hürthle cell carcinoma [(n=1) 2%] and anaplastic thyroid
carcinoma [(n=1) 2%]., the blood group A with Rh positive was
the most frequent [n= 17, (34%)], , the O+ve was [n=15 (30%)],
B+ve [n=10 (20%)], while AB-ve [n=3 (6%)] while a small
number was Rhesus negative. The A+ve blood group was the
commonest blood group in PTC patients (34.8%), followed by
O+ve (30.4%).
Conclusion: Blood group A+ve is the most frequently reported
among cases of papillary thyroid carcinoma, which is the most
common MTT.


Wartofsky L, Van Nostrand D. Thyroid cancer: a comprehensive

guide to clinical management: Springer; 2006.

Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for

thyroid carcinoma: A population‐based study of 15,698 cases from the

Surveillance, Epidemiology and End Results (SEER) Program 1973–1991.

Cancer: Interdisciplinary International Journal of the American Cancer Society.


Yang H, Yan J. A systematic review of prognosis of ABO blood

group and rhesus factor on outcomes in patients with bladder cancer. Medicine.


Wang J, García-Bailo B, Nielsen DE, El-Sohemy A. ABO

genotype,‘blood-type’diet and cardiometabolic risk factors. PloS one.


Liumbruno GM, Franchini M. Hemostasis, cancer, and ABO blood

group: the most recent evidence of association. Journal of thrombosis and

thrombolysis. 2014;38:160-6.

Kim D-S, Scherer PE. Obesity, diabetes, and increased cancer

progression. Diabetes & metabolism journal. 2021;45(6):799-812.

Hovinga ICK, Koopmans M, de Heer E, Bruijn JA, Bajema IM.

Change in blood group in systemic lupus erythematosus. The Lancet.


Edition S, Edge S, Byrd D. AJCC cancer staging manual. AJCC

cancer staging manual. 2017.

Lang TA, Secic M. How to report statistics in medicine: annotated

guidelines for authors, editors, and reviewers: ACP Press; 2006.

Habibzadeh F. Common statistical mistakes in manuscripts submitted

to biomedical journals. European Science Editing. 2013;39(4):92-4.

Habibzadeh F. Statistical data editing in scientific articles. Journal of

Korean medical science. 2017;32(7):1072-6.

Karhu D, Vanzieleghem M. Significance of digits in scientific

research. AMWA J. 2013;28(2):58-60.

Jonklaas J, Nogueras-Gonzalez G, Munsell M, Litofsky D, Ain K,

Bigos S, et al. The impact of age and gender on papillary thyroid cancer survival.

The Journal of Clinical Endocrinology & Metabolism. 2012;97(6):E878-E87.

Rahbari R, Zhang L, Kebebew E. Thyroid cancer gender disparity.

Future Oncology. 2010;6(11):1771-9.

Yager J, Leihr J. Molecular mechanisms of estrogen carcinogenesis.

Annual review of pharmacology and toxicology. 1996;36(1):203-32.

Lee M, Chen G, Vlantis A, Tse G, Leung B, Van Hasselt C. Induction

of thyroid papillary carcinoma cell proliferation by estrogen is associated with an

altered expression of Bcl-xL. The Cancer Journal. 2005;11(2):113-21.

Zeng Q, Chen G, Vlantis A, Van Hasselt C. Oestrogen mediates the

growth of human thyroid carcinoma cells via an oestrogen receptor–ERK

pathway. Cell Proliferation. 2007;40(6):921-35.

Ortega J, Sala C, Flor B, Lledo S. Efficacy and cost-effectiveness of

the UltraCision® harmonic scalpel in thyroid surgery: an analysis of 200 cases in

a randomized trial. Journal of Laparoendoscopic & Advanced Surgical

Techniques. 2004;14(1):9-12.

Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated

thyroid cancer in the United States, 1988–2005. Cancer: Interdisciplinary

International Journal of the American Cancer Society. 2009;115(16):3801-7.

Moysich KB, Menezes RJ, Michalek AM. Chernobyl-related ionising

radiation exposure and cancer risk: an epidemiological review. The Lancet

Oncology. 2002;3(5):269-79.

Cardis E, Kesminiene A, Ivanov V, Malakhova I, Shibata Y, Khrouch

V, et al. Risk of thyroid cancer after exposure to 131 I in childhood. Journal of

the National Cancer Institute. 2005;97(10):724-32.

Parad MT, Fararouei M, Mirahmadizadeh AR, Afrashteh S. Thyroid

cancer and its associated factors: A population‐based case‐control study.

International Journal of Cancer. 2021;149(3):514-21.

LeClair K, Bell KJ, Furuya-Kanamori L, Doi SA, Francis DO, Davies

L. Evaluation of gender inequity in thyroid cancer diagnosis: differences by sex

in US thyroid cancer incidence compared with a meta-analysis of subclinical

thyroid cancer rates at autopsy. JAMA Internal Medicine. 2021;181(10):1351-8.

Franceschi S, Boyle P, Maisonneuve P, La Vecchia C, Burt AD, Kerr

DJ, et al. The epidemiology of thyroid carcinoma. Critical reviews in

oncogenesis. 1993;4(1):25-52.

Davies L, Welch HG. Increasing incidence of thyroid cancer in the

United States, 1973-2002. Jama. 2006;295(18):2164-7.

Zhu C, Zheng T, Kilfoy BA, Han X, Ma S, Ba Y, et al. A birth cohort

analysis of the incidence of papillary thyroid cancer in the United States, 1973–

Thyroid. 2009;19(10):1061-6.

Howlader N, Noone A, Krapcho M, Miller D, Bishop K, Altekruse S,

et al. SEER Cancer Statistics Review, 1975–2013. Bethesda, MD: National

Cancer Institute; 2016. 2016.

Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. The

Lancet. 2016;388(10061):2783-95.

Bonnefond S, Davies TF. Thyroid cancer—risks and causes. JournalThyroid Cancer—Risks and Causes. 2014.

Reid ME, Mohandas N, editors. Red blood cell blood group antigens:

structure and function. Seminars in hematology; 2004: Elsevier.

Tam AA, Özdemir D, Fakı S, Bilginer MC, Ersoy R, Çakır B. ABO

blood groups, Rh factor, and thyroid cancer risk: to ‘B’or not to ‘B’. Endocrine

research. 2020;45(2):137-46.

Franchini M, Liumbruno GM. ABO blood group: old dogma, new

perspectives. Clinical Chemistry and Laboratory Medicine (CCLM).


Edgren G, Hjalgrim H, Rostgaard K, Norda R, Wikman A, Melbye M,

et al. Risk of gastric cancer and peptic ulcers in relation to ABO blood type: a

cohort study. American journal of epidemiology. 2010;172(11):1280-5.

Hakomori S-i. Antigen structure and genetic basis of histo-blood

groups A, B and O: their changes associated with human cancer. Biochimica et

Biophysica Acta (BBA)-General Subjects. 1999;1473(1):247-66.

Zhang B-L, He N, Huang Y-B, Song F-J, Chen K-X. ABO blood

groups and risk of cancer: a systematic review and meta-analysis. Asian Pacific

Journal of Cancer Prevention. 2014;15(11):4643-50.

Coussens LM, Werb Z. Inflammation and cancer. Nature.


Li C, Xu F, Huang Q, Han D, Zheng S, Wu W, et al. Nomograms for

differentiated thyroid carcinoma patients based on the eighth AJCC staging and

competing risks model. JNCI Cancer Spectrum. 2021;5(3):pkab038.

Kakudo K, Tang W, Ito Y, Mori I, Nakamura Y, Miyauchi A.

Papillary carcinoma of the thyroid in Japan: subclassification of common type

and identification of low risk group. Journal of clinical pathology.